Back to Journals » Cancer Management and Research » Volume 12

LncRNA PSMA3-AS1 Promotes Lung Cancer Growth and Invasion via Sponging MiR-4504

Authors Li F, Yu L, Zhu J

Received 12 March 2020

Accepted for publication 28 May 2020

Published 1 July 2020 Volume 2020:12 Pages 5277—5283


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Eileen O'Reilly

Fangfang Li,1 LianLing Yu,1 Jun Zhu2

1Department of Respiration Medicine, Qingdao Eighth People’s Hospital, Qingdao 266000, People’s Republic of China; 2Department of Inspection, The 5th People’s Hospital of Jinan, Jinan 250022, People’s Republic of China

Correspondence: Jun Zhu Email

Background: Long noncoding RNAs (lncRNAs) have close correlation with tumorigenesis. And how lncRNAs participate in lung cancer require investigation in-depth. The aim of this study was to determine the role of lncRNA PSMA3-AS1 in lung cancer progression.
Methods: PSMA3-AS1 expression was analyzed via qRT-PCR. Kaplan–Meier method was used to analyze survival rate based on PSMA3-AS1 value. Proliferation was measured via CCK8 and colony formation assays. Transwell assay was utilized to examine migration and invasion. Luciferase reporter assay and RNA pulldown assay were utilized to analyze the interaction between PSMA3-AS1 and miR-4504.
Results: PSMA3-AS1 expression was upregulated in lung cancer tissues and cell lines. PSMA3-AS1 expression was positively correlated with clinical stage and metastasis. PSMA3-AS1 overexpression predicted a poor prognosis in lung cancer patients. PSMA3-AS1 knockdown suppressed proliferation, migration and invasion of lung cancer cells. Through bioinformatics analysis, PSMA3-AS1 was predicted to sponge miR-4504. MiR-4504 expression was inhibited by PSMA3-AS1. And inhibition of miR-4504 reversed the effects of PSMA3-AS1 depletion.
Conclusion: PSMA3-AS1 promotes the tumorigenesis of lung cancer through inhibiting miR-4504.

Keywords: PSMA3-AS1, miR-4504, lung cancer, progression

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]